The effects of valproic acid on the mRNA expression of Natriuretic Peptide Receptor A and KQT-like subfamily Q-1 in human colon cancer cell lines by Hajikazemi, Mona et al.
Alexandria Journal of Medicine 54 (2018) 17–22Contents lists available at ScienceDirect
Alexandria Journal of Medicine
journal homepage: ht tp : / /www.elsevier .com/locate /a jmeOriginal ArticleThe effects of valproic acid on the mRNA expression of Natriuretic
Peptide Receptor A and KQT-like subfamily Q-1 in human colon cancer
cell lineshttp://dx.doi.org/10.1016/j.ajme.2017.04.002
2090-5068/ 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of Alexandria University Faculty of Medicine.
⇑ Corresponding author.
E-mail address: Mohsen.saeedi@gmail.com (M. Saeedi).Mona Hajikazemi a, Hoda Sohrabi a, Ahad Yamchi b, Mohsen Saeedi c,⇑
aDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran
bDepartment of Plant Breeding and Biotechnology, College of Plant Production Gorgan University of Agriculture Science and Natural Recourses, Gorgan, Iran
c Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
a r t i c l e i n f oArticle history:
Received 24 October 2016
Revised 15 March 2017
Accepted 10 April 2017
Available online 28 April 2017
Keywords:
Colorectal cancer
Human colorectal cancer cell lines
KCNQ1
Natriuretic Peptide Receptor A
Valproic acida b s t r a c t
Aim and objectives: The histone deacetylase (HDAC) inhibitor, Valproic Acid (VPA), causes growth inhibi-
tion and apoptosis in colorectal cancer cells. HDAC inhibition is associated with the transcriptional reg-
ulation of Natriuretic Peptide Receptor-A (NPR-A). NPR-A regulates voltage-gated potassium channel,
KQT-like subfamily Q, member 1 (KCNQ1). NPR-A and KCNQ1 are also involved in the initiation and prop-
agation of cancer cells. In this study, we investigated the simultaneous expressional changes of NPR-A
and KCNQ1 among VPA-treated colon cancer cells.
Materials and methods: Human colorectal cancer cells were cultured and treated with increasing concen-
trations of VPA at different time points. MTT viability test was conducted to evaluate the growth inhibi-
tion. Real Time RT-PCR was used to quantify differential mRNA expression of NPR-A and KCNQ1 genes.
Two-way ANOVA and bonferroni post-tests were used to analyze data statistically.
Results: We showed that VPA treatment inhibits the growth of SW-480 cells more efficiently compared to
HT-29. NPR-A and KCNQ1 genes were significantly upregulated upon VPA treatment in both cell lines
(P < 0.0001).
Conclusion: The alteration of NPR-A and KCNQ1 genes were more ordered among SW-480 cancer cells.
The expressional changes of KCNQ1 and NPR-A among VPA treated human colon cancer cells follow
the same pattern in similar combinations. VPA could regulate the expression of KCNQ1 through altering
the mRNA expression of NPR-A.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) encompasses a heterogeneous and
tumor specific complex of diseases resulting from different alter-
ations in genetic and epigenetic molecular pathways.1 It is the
third most common cancer and third leading cause of cancer death
in the United States.1 Modification of histones is an epigenetic pro-
cess which is involved in gene regulation while inhibitors of His-
tone deacetylases (HDACs) are introduced as a novel therapeutic
class of drugs against different cancer types.2,3 HDAC inhibitors
regulate the expression of genes which are involved in specific bio-
logical responses such as apoptosis, immune regulation and angio-
genesis.4–6 Valproic Acid (VPA) is a branched, short-chain fatty acidwhich acts as a HDAC1 and HDAC2a inhibitor. VPA is an estab-
lished anti-epileptic drug7 which is shown to induce differentiation
and apoptosis in a variety of carcinoma cells.8,9 VPA has been also
introduced as an antiproliferative compound in CRC, alone or in
combination with other therapeutic strategies.10
HDAC inhibitors modulate the transcriptional regulation of
Natriuretic Peptide Receptor-A (NPR-A).11,12 NPR-A is overex-
pressed in numerous human cancer cells including colon adenocar-
cinoma13–17 and could be introduced as a novel anticancer
target.15,18 Atrial Natriuretic Peptide (ANP) is the specific ligand
for NPR-A19 which regulates the proliferation of human gastric
cancer cells via K+ voltage-gated channel subfamily Q member 1
(KCNQ1; also known as LQT1).20 KCNQ1 has been also introduced
as a novel regulator of cancer cell proliferation and migration in
different cancer types.20–22 Moreover, HDAC inhibitors are
reported to be capable of regulating the transcription of ATP sensi-
tive K+ (KATP) channels,23 which has not been reported among
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gated the effect of VPA as a HDAC inhibitor on the expression of
NPR-A and KCNQ1 and also the possible simultaneous alterations
of these genes in response to VPA in colon adenocarcinoma cancer
cell lines.2. Materials and methods
2.1. Cell culture and treatments
HT-29 and SW-480 human colon adenocarcinoma cells were
purchased from National Cell Bank of Iran (Pasteur Institute, Iran)
and cultured in RPMI 1640 (Gibco, Life Technologies, USA). HCT-
116 and Caco-2 colon adenocarcinoma cells were also purchased
from National Cell Bank of Iran (Pasteur Institute, Iran) and cul-
tured in DMEM (Gibco, Life Technologies, USA). All cell culture
media were supplemented with 10% FBS, 100U/ml penicillin and
100 lg/ml streptomycin. Tissue culture flasks were incubated in
a fully humidified atmosphere at 37 C with 5% CO2. 0.5  106
cells/mL were counted and seeded in each well of 6-well tissue cul-
ture plates followed by resuspension in complete growth media
and incubated for 24 h in order to keep cells in logarithmic phase
growth. HT-29 and SW-480 cells were treated with the most
antiproliferative concentrations of VPA (Sigma-Aldrich, USA)
(1 mM, 2 mM and 4 mM) with the least cytotoxicity effects on nor-
mal cells.24 Treated and non-treated cells were then incubated for
different time points (24, 48 and 72 h). Finally, the cells were
detached using 0.025% trypsin-EDTA (Gibco, Life Technologies,
USA) for consequent RNA extraction.
2.2. Total RNA extraction and Real Time RT-PCR
Total RNA was extracted using Biozol (Bioer, China) according
to the manufacturer’s protocol. To remove any genomic DNA con-
tamination, 1 microgram of total RNA was used for DNase I (Cinna-
Gen, Iran) digestion and were reverse transcribed to cDNA using
random hexamer primers (Bioron, Germany). Real-time RT-PCR
was performed with Bioer Real-time PCR detection system (Bioer
Technology, China) and Bioron SYBR green master mix (Bioron,
Germany). Human 18S ribosomal RNA (18s rRNA) was used as a
consistent internal control for gene expression normalization.25
Gene specific primers which were designed to span exons for
KCNQ1, NPR-A and 18s rRNA are summarized in Table 1. All data
are presented as fold changes compared to non-treated cells.
2.3. Cell viability (MTT) assay
The cells were counted, seeded in 96-well plate (104 cells/well)
and incubated for 24 h in complete culture media. The cells were
then treated with different increasing concentrations of VPA
(1 mM, 2 mM and 4 mM) at different time intervals (24, 48 and
72 h). After each time point, the complete culture media was
removed and a final volume of 80 ll of Phenol Red free RPMITable1
Gene specific primers used for Real Time RT-PCR.
Primer (accession) Sequence (50 > 30) Tm Amplicon
size (bp)
KCNQ1 (NM_000218.2) TGTCCACCATCGAGCAGTATG 61.5 84
CCGTCCCGAAGAACACCAC
NPRA (NM_000906.3) GTCAACACAGCCTCAAGA 60.1 136
CCTTTGCCCTTCATTTCTAC
18srRNA (M10098) CAGCCACCCGAGATTGAGCA 60.7 252
TAGTAGCGACGGGCGGTGTG1640 (Gibco, Life Technologies, USA) with 20 ll of MTT solution
(5 mg/mL) were added to each well and incubated for 4 h at
37 C with 5% CO2. 100 ll DMSO was then added to each well as
a cell lysis solution. Percentage of cell viability was assessed by
spectrophotometry at 570 nm using ELx800 Absorbance Reader
(Biotek, USA).
2.4. Statistical analysis
All of the experiments for each sample were repeated in tripli-
cates and data were demonstrated as means ± SE (Standard Error).
Statistical software SPSS22.0 and Graphpad Prism 5.04 were used
for data analysis. Two-Way ANOVA with Bonferroni post hoc test
was used for comparing means of multiple samples. P-values lower
than 0.05 were considered as statistically significant.
3. Results
3.1. The mRNA expression level of NPR-A and KCNQ1 among different
human colon cancer cell lines
The expression levels of NPR-A and KCNQ1 were quantified
among four different human colon adenocarcinoma cell lines
including HCT-116, SW-480, HT-29 and Caco-2. NPR-A was overex-
pressed in SW-480 and HT-29 cells in comparison to HCT-116Fig. 1. The mRNA expression level of NPRA and KCNQ1. NPRA and KCNQ1 are
overexpressed in HT-29 (A) and SW-480 (B) cell lines in comparison to other human
colon cancer cells. Data are expressed relatively to mRNA levels in HCT 116 cell line,
arbitrarily set at the value of 1. Data are obtained from experiments in triplicates
and presented as means ± SE. Significant differences are evaluated using indepen-
dent samples t-test. P-values lower than 0.05 are considered statistically significant.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns: not significant.
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statistically different compared to HCT-116. KCNQ1 was also over-
expressed among HT-29 and SW-480 cells (Fig. 1B). Accordingly,
HT-29 and SW-480 with the highest expression of NPR-A and
KCNQ1 were chosen for the next phase of the study.3.2. VPA is an effective inhibitor of proliferation in human colon cancer
cells
To measure the effects of VPA on cell viability, various increas-
ing concentrations of VPA were applied to cell culture medium of
SW-480 and HT-29 cancer cells at different time intervals
(Fig. 2A). Percentages of viable cells were measured by MTT Assay.
VPA treatment has reduced the viability of HT-29 (Fig. 2B) and SW-
480 (Fig. 2C) cells significantly after 24, 48 and 72 h. VPA is a more
effective inhibitor of proliferation on SW-480 cancer cells.3.3. The expression pattern of NPR-A is different among HT-29 and
SW-480 cell lines
During the first 24 h, NPR-A was significantly overexpressed in
HT-29 cells at 1 mM concentration of VPA. After 48 h, NPR-A was
downregulated by increasing the concentrations of VPA. However,
no significant difference was observed. However, NPR-A was ele-
vated gently with increasing VPA concentrations after 72 h
(Fig. 3A).Fig. 2. Effects of VPA on cell proliferation in vitro. (A) Growth inhibition was observed up
72 h) on HT-29 and SW480 cells. MTT assay was performed to determine the proliferatio
of SW480 and HT-29 cells in a concentration and time dependent manner. Data represe
evaluated using independent samples t-test. P-values lower than 0.05 are considered sta
cells (mock).Unlike HT-29 cells, NPR-A was overexpressed among SW-480
cells in an ordered manner after 24 and 48 h. SW-480 cells treated
with 4 mM VPA showed the highest expression of NPR-A. After
72 h, the expression of NPR-A decreased in all treatments and
was the same as non-treated SW-480 cells (Fig. 3B).
3.4. KCNQ1 is overexpressed among HT-29 and SW-480 cells in
response to VPA
KCNQ1 was elevated gradually among HT-29 colon cancer cells
proportional to the increasing concentrations of VPA after 24 and
48 h. HT-29 cancer cells showed the highest expression level of
KCNQ1 at 4 mM VPA treatment after 48 h. KCNQ1 was downregu-
lated after 72 h among VPA treated HT-29 cells except for 4 mM
concentration (Fig. 4A). KCNQ1 increased significantly among
SW-480 cells only after 48 h of incubation in all concentrations
(Fig. 4B).
3.5. Concurrent alterations of KCNQ1 and NPRA in colon cancer cells
In order to estimate the probable simultaneous changes in the
expression of NPR-A and KCNQ1 in human colon cancer cell lines,
the expression pattern of all concentrations at each time point
were adapted to its relevant. There was a correlation between
the expressional changes of NPR-A and KCNQ1 among SW-480
cells. In all concentration of VPA and all tested time points, altering
the expression of NPR-A directly affected the expression of KCNQ1.on VPA treatments (1 mM, 2 mM and 4 mM) at different time points (24 h, 48 h and
n of HT-29 (B) and SW-480 (C) human colon cancer cells. VPA inhibited cell viability
nt the mean ± SE from three independent experiments. Significant differences are
tistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NC: non-treated
Fig. 3. NPRA expressional alterations. The mRNA expressional changes of NPRA
were quantified by Real-Time RT-PCR in each combination representing different
patterns among HT-29 (A) and SW-480 (B) human colon cancer cells. Data are
expressed relatively to mRNA levels in non-treated (NC) cell lines, arbitrarily set at
the value of 1. Data are obtained from experiments in triplicates and presented as
means ± SE. Significant differences are evaluated using independent samples t-test
or one-way ANOVA followed by bonferroni post hoc test while studying multiple
comparisons. P-values lower than 0.05 are considered statistically significant.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NC: non-treated cells (mock).
Fig. 4. Overexpression of KCNQ1 upon VPA treatment. The mRNA expression levels
of KCNQ1 were quantified by Real-Time RT-PCR in each combination among HT-29
(A) and SW480 (B) human colon cancer cells. KCNQ1 is overexpressed in all VPA
treated colon cancer cells. Data are expressed relatively to mRNA levels in non-
treated (NC) cell lines, arbitrarily set at the value of 1. Data are obtained from
experiments in triplicates and presented as means ± SE. Significant differences are
evaluated using independent samples t-test or one-way ANOVA followed by
bonferroni post hoc test while studying multiple comparisons. P-values lower than
0.05 are considered statistically significant. ***P < 0.001, ****P < 0.0001, NC: non-
treated cells (mock).
20 M. Hajikazemi et al. / Alexandria Journal of Medicine 54 (2018) 17–22Such a concordance between the expression of NPR-A and KCNQ1
is observed in HT-29 cells except for treatments at 4 mM VPA
(Fig. 5).4. Discussion
Histone deacetylation is an epigenetic modification in gene
expression which has diverse effects on gene function, malignant
cellular transformation, cell cycle and apoptosis.5,26,27 These bio-
logical and pathological mechanisms are commonly modified by
HDAC inhibitors which mostly possess anticancer properties.2,3,11
VPA is a HDAC1 and HDAC2a inhibitor which has been utilized in
the therapy of epilepsy for a long time.7,8,23 VPA alongside with
other HDAC inhibitors have shown promising antiproliferative
effects in different cancers including CRC.28–30 Moreover, the com-
bination of VPA with conventional anticancer therapies has
enhanced the effectiveness of current.30,31
Here, we conducted MTT viability test to measure the growth
inhibitory effects of various concentrations of VPA on SW-480
and HT-29 cancer cells. The antiproliferative effects of VPA have
been evaluated in different colon cancer cell lines. According to
these reports, SW-480 is one of the most sensitive colon cancer cell
lines to VPA treatment.28 On the other hand, it has been reported
that HT-29 as an APC mutant CRC cell line is less sensitive to
VPA.29 We showed that, VPA treatment has reduced the viabilityof SW-480 and HT-29 cells after each treatment. In accordance
with the previous studies, we noted that VPA is a more effective
proliferation inhibitor on SW-480 cancer cells compared to HT-
29. However, VPA still preserves its growth inhibitory properties
against HT-29 cells especially at higher concentrations.
NPR-A which is one of the specific receptors for ANP cardiac
hormone is expressed in numerous human cancer cells including
CRC.15,18 NPR-A is involved in different physiological and patholog-
ical processes and has been recently introduced as a novel anti-
cancer target.20,32 However, there is no record available
comparing the expression level of NPR-A among different human
CRC cell lines.33 In order to target the CRC cell lines with the over-
expression of NPR-A, we examined the expression of NPR-A among
four different human CRC cell lines including HCT-116, SW-480,
HT-29 and Caco-2. The lowest expression was demonstrated in
HCT-116. The expression level of NPR-A was higher among SW-
480 and HT-29 cells compared to HCT-116. We also quantified
the expression of KCNQ1 gene among all CRC cell lines. Similar
to the expression pattern of NPR-A, the mRNA expression of
KCNQ1 was higher in SW-480 and HT-29 cells. Therefore, SW-
480 and HT-29, with different molecular characteristics, were
selected to be studied. These CRC cell lines could be appropriate
in vitro models to investigate NPR-A mediated novel anticancer
strategies. The expression of NPR-A was not statistically different
in Caco-2 compared to HCT-116.
Fig. 5. NPRA and KCNQ1 simultaneous mRNA expression patterns. The quantified
mRNA expression of NPRA and KCNQ1 genes were compared in order to derive a
possible alteration pattern. We showed that the expressional changes in NPRA and
KCNQ1 occur concurrently among SW-480 human colon cancer cells (B) and not
HT-29 (A). Data are obtained from experiments in triplicates and presented as
means. NC: non-treated cells (mock).
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by blocking HDACs and interacting with Sp1, histone acetyltrans-
ferase, and acetylated histones.11 Kumar et al claimed that
Trichostatin-A (TSA) as a class I HDAC inhibitor modulates the
transcriptional regulation of NPR-A gene.12 On the other hand, it
was revealed that NPR-A knockdown could downregulate the
expression of voltage-gated potassium channel, KCNQ1.20 KCNQ1
channel has been introduced as a novel regulator of cancer cell pro-
liferation in many human cancer cells including CRC. HDAC inhibi-
tors can regulate the ATP sensitive K+(KATP) channels subunit
transcription in cardiomyocytes as well,23 but to date no study
has explained the possible effects of HDAC inhibition on the
expression of voltage-gated K+ channels including KCNQ1.
We postulated that the effects of VPA might be carried out
through regulating the expression of NPR-A and consequently
KCNQ1. Therefore, we aimed to investigate the anticancer effects
of various concentrations of VPA at different time points on
selected CRC cell lines by quantifying the alterations in the expres-
sion of NPR-A and KCNQ1 genes and the possible relation between
the these two genes.
VPA might have a more transient effect on the expression of
NPR-A among HT-29 CRC cancer cells. We noted that, at lower con-
centrations of VPA which induce the least toxicity, NPR-A is over-
expressed but an unclear mechanism (maybe a negative feedback)
reverses the expression pattern of NPR-A after 24 h and the
expression was reduced. Unlike HT-29 cells, the transcriptional
effect of VPA on the expression of NPR-A is more persistent amongSW-480 cells. The expression of NPR-A is finally decreased in all
treatments and reaches the same as non-treated SW480 cells.
Moreover, KCNQ1 is overexpressed among HT-29 and SW-480
colon cancer cells in response to VPA. This overexpression is more
vividly observed among HT-29 cells in higher concentrations of
VPA at all-time points. The expression level of KCNQ1 among
SW-480 cells increased only after 48 h of incubation in all concen-
trations. The alterations in the expression of NPR-A and KCNQ1
among SW-480 cells occur simultaneously with the same pattern.
This pattern was also observed in the expression of NPR-A and
KCNQ1 among HT-29 cells with minimal irregularity. Accordingly,
VPA alters the expression of NPR-A and KCNQ1 with the same pat-
tern. However, these alterations are more ordered among SW-480
human CRC cells.
5. Conclusion
VPA mediates its effects on human CRC cell lines through alter-
ing the expression of NPR-A and KCNQ1 simultaneously. These
alteration patterns are more ordered among SW-480 cancer cells.
We propose the alterations in the expression of NPR-A and KCNQ1
as a novel molecular mechanism of effect for the effects of VPA in
CRC. Our findings need to be investigated in further experiments
using more sophisticated in vitro or in vivo examinations.References
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